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Introduction
Obstructive sleep apnea (OSA) is a disorder characterized by short apneas or hypopneas
during sleep. These pauses in breathing lead to disruption of sleep and hypoxemia. The
diagnosis could be done by polysomnography or by a home sleep apnea study at home
[1]. If untreated, sleep apnea may aggravate or even cause a variety of diseases, such as
cardiovascular and metabolic diseases [2, 3]. The current treatment for sleep apnea, along
with lifestyle counseling, is positive airway pressure (PAP) treatment. PAP uses positive
pressure to assist the patient’s own breathing and helps keep the airway open during sleep
[3, 4]
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PAP treatment is administered via a mask that is worn while sleeping [5]. The treatment
is generally not well tolerated, mainly due to discomfort [6].
There are few studies regarding eye symptoms with PAP therapy. Hayirci et al showed
an increase in Nelson classification of squamous metaplasia score and in Schirmer 1 score
in the right eye with short-term PAP therapy [7]. A case study by Harrison et al showed
three patients that experienced dryness and irritation of the eyes after PAP initiation [8].
Conversely, Kadyan et al [9] showed that in obstructive sleep apnea patients the
continuous use of PAP diminishes ocular symptoms and improves tear film compared to
non-users, mainly due to better sleeping habits and posture. Acar et al [10] showed similar
findings with long-term use. There are also sporadic reports of eye symptoms caused by
air regurgitation through the nasolacrimal system with PAP use [11-13].
In this pilot  study, we evaluated eye symptoms before PAP initiation, a few days after
PAP initiation and at 2-3 months of PAP therapy. We were interested in determining if
there was any change in eye symptoms during PAP therapy.
Methods
Sleep apnea patients referred to our Sleep Unit for PAP initiation were asked to complete
a questionnaire about their eye symptoms at baseline, 3-5 days after initiation and at 2-3
months of PAP therapy. Our unit is a tertiary referral centre for obstructive sleep apnea.
For each patient, our sleep nurses carefully selected the most suitable mask interface and
checked for a possible disturbing leak before starting PAP therapy. Furthermore our
nurses observed the patients’ facial shapes and verified the direction of the intentional air
leak emerging from the vent before choosing the best suitable mask.
The questionnaire consisted of four questions:
Question 1:  Have you had any eyelid or lacrimal surgery? Yes/no, if yes then specify.
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Question 2: Do you have any dry eye symptoms? i.e. you have a foreign body sensation
or your eyes are easily irritable and become red (for example in windy weather).
The patient placed a mark over a Visual Analog Scale (VAS) ranging from 0 (symptom
free) to 100 (severe symptoms).
Dry eye symptom values were derived from this question.
Question 3: Do you have eye watering while indoors?
This  question  was  also  scored  on  a  VAS ranging  from 0  (no  watering)  to  100  (severe
watering). This question was asked separately for the right and the left eye.
Left and right watering values were derived from this question.
Question 4: Do you use artificial tears? Yes/no, if yes, then please indicate the brand and
the dose.
Patient characteristics and PAP data:
Data from the patient file about comorbidities, allergies, medications, BMI and age was
collected. Additional data was obtained from the ResScan program regarding the
following PAP parameters: apnea and hypopnea index (AHI), oxygen desaturation index
of 3 % (ODI3), mask leak, mask type, mask brand, daily PAP use, pressure, pulse and
SpO2.
A patient was considered PAP adherent if the use of PAP therapy was 4 hours or more
per day. Conversely, a patient was considered non-adherent if the use was under 4 hours.
We used the age-adjusted Charlson comorbidity index (CCI) to evaluate comorbidity.
This index encompasses 19 medical conditions weighted from 1 to 6 with total scores
ranging from 0 to 37 (0 = no comorbidity) [14].
The study was approved by the Helsinki University Hospital authorization committee
(code 4/2016, date 15.8.2016).
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Statistics
Results were generated using a computerized statistical package (IBM SPSS® Statistics
21.0, Armonk, NY, USA). Data was checked for normality using Shapiro-Wilk methods.
All p-values were two-sided, and the significance level was set at 0.05 throughout. Eye
symptoms at baseline and with PAP were compared using paired t-test when applicable.
ANOVA and Chi test were used when appropriate. We also used the bivariate Pearson
correlation.
Results
We included 46 patients (14 women). Mean age ± SD was 56.0 ± 15.9, mean BMI 31.7
± 6.0, mean AHI 34.1 ± 21.8, mean ODI3 34.4 ± 20.7, mean oxygen saturation 91.6 ±
2.9, mean nadir SpO2 79.1 ± 8.2%, mean CT90% (cumulative time with SpO2 under
90%) 20.9 ± 26.8 and mean CCI 1.8 ± 2.3 (Table 1). Out of the 46 participants, 45
answered the questionnaire at baseline, 39 at four days and 24 at two months.
Dry eye symptom values
The mean ± SD dry eye symptom values at baseline were 27.5 ± 26.6, at four days of
PAP therapy 28.7 ± 26.0 and at two months 30.0 ± 28.2. We did not find a significant
difference between these groups [F (2, 108) = 0.071; (p = 0.932)] (Figure 1).
Seven patients regularly used artificial tears. Despite artificial tear therapy, the dry eye
symptom values at baseline in these patients were slightly higher than the rest of the
group, but did not reach a statistically significant difference (34.4 ± 16.4 vs. 26.3 ± 28.0,
respectively, [F (1, 44) = 0.553; (p = 0.461)].
Eight patients reported using medications that may cause dry eye symptoms. None of
these patients discontinued PAP therapy during this study. Moreover, their dry eye
symptom values did not differ significantly from the rest of the study group (28.4 ± 30.4
vs. 27.4 ± 26.1, respectively [F (1, 44) = 0.010; (p = 0.923)].
Four patients reported previous eyelid surgery; eye symptoms in these patients did not
differ from the rest of the study population.
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Watering values
No significant difference in the watering value for the right eye was found between
baseline (17.7 ± 22.0), at four days (15.6 ± 21.3) or at two months (21.0 ± 26.4) [F (2,
108) = 0.408; (p = 0.666)]. The left eye showed similar results: 16.9 ± 20.7(baseline),
16.3 ± 21.7 (four days) and 21.3 ± 25.5 (two months) [F (2, 108) = 0.418; (p = 0.659)]
(Figure 2).
Mask air leak
We tested if there was any correlation between the severity of eye symptoms and PAP
mask leaking. We found a statistically significant correlation between the severity of the
95th percentile mask leak and the watering values in the left or right eye at two months of
PAP therapy (Pearson correlation r = 0.393, n = 48, p = 0.006) (Figure 3). No correlation
was found regarding dry eye symptom values and air leak.
Mask type and brand
Six patients initially used nasal pillow masks, 34 patients used nasal masks and for six
patients  a  full  face  mask  was  chosen.  Four  patients  had  F&P  masks  and  the  rest  had
Resmed masks. All patients had an additional humidifier. For two patients, we switched
their nasal mask to a full face mask to reduce mouth air leak. We did not find any
significant difference in eye symptoms related to the type or the brand of the mask at
baseline, at four days or two months of PAP use. We also did not find any difference in
the 95th percentile of mask leak between mask types.
PAP adherence
Non-adherent PAP patients had significantly higher dry eye symptom values at baseline
(37.6 ± 30.6) than the adherent patients (18.8 ± 19.0) [F (1, 44) = 6.307; (p = 0.016)].
This difference became more prominent at two months of PAP therapy: 50.4 ± 27.2 (non-
adherent) vs. 15.5 ± 18.8 (adherent) [F (1, 23) = 13.929; (p = 0.001)].
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We also found a similar difference in the watering values at two months of PAP therapy
in these groups: 32.6 ± 27.3 (non-adherent) vs. 12.9 ± 21.3 (adherent) [F (1, 47) = 7.874;
(p = 0.007)].
Discontinuing vs. continuing PAP
Five patients discontinued PAP therapy during the study. The mean dry eye symptom and
watering values at baseline and the 95th percentile air leak values in these patients did not
differ from the rest of the subjects.
Discussion
In this pilot study, we found no significant change in the patient eye symptoms with short-
term PAP therapy.
Hayirci et al [7] have reported an increase in ocular irritation, tear evaporation and
squamous metaplasia in the conjunctiva of the patients' right and left eyes with short-term
CPAP therapy. The authors suggested that their observations may be due to a contact
between the mask and the ocular surface, or dislocation or misplacement (or both) of the
PAP mask leading to air leak. We believe that air leak from the mask directed to the eyes,
intentional or unintentional, may play a major role in exacerbating or causing eye
symptoms. In this study, we observed some correlation between mask leak and severity
of eye watering.
We found no significant differences in eye symptoms related to the type of PAP mask
used. We have previously reported that a disturbing air leak is not correlated to the amount
of measured leak [15]. Leaks directed to the eye area may induce eye symptoms during
PAP therapy. To avoid this problem, our sleep nurses carefully selected the most suitable
mask interface for each patient and checked for a possible disturbing leak before starting
PAP therapy. The nurses took in consideration the direction of the intentional air leak
emerging from the vent and the patients’ facial shapes. We believe that these precautions
could in part explain the absence of change in eye symptoms during this study and also
the absence of differences in mask leak between those who discontinued PAP therapy and
those who continued PAP therapy.
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Our results agree with the findings of Kadyan et al. [9]. The authors reported amelioration
in ocular symptoms and improvement in tear film with continuous PAP therapy compared
to no therapy. They explained that these changes were due to better sleeping habits and
sleeping posture. We do not have an explanation for this finding, meanwhile we noticed
that our adherent PAP patients had significantly lower dry eye symptom values than the
other patients.
Seven of our patients regularly used artificial  tears,  indicating the existence of dry eye
disease in 15% of our studied sleep apnea patients referred for PAP therapy. We found
no comparison values for this reported percentage in the literature. In the general
population, the prevalence of dry eye disease varies between 5 and 35% [16-18]. The real
prevalence of dry eye disease among sleep apnea patients is unknown. Nevertheless,
Hsiao et al., [19] have studied subjects without sleep apnea but suffering from sleep
disorders. These researchers reported a higher prevalence of Sjögren syndrome in the
subjects with sleep disorders than in those without. We believe that sleep apnea patients
suffer more often from dry eye disease than the general population. This possibility needs
to be confirmed in the future.
Limitations of the study
Our study has some limitations. As this is a pilot study, no statistical power calculations
were done. Our follow-up time was relatively short (two months). We have previously
reported cases of eye symptoms evolving years after PAP initiation [11]. We did not
measure eye symptoms objectively, an ophthalmologist did not examine the patients and
we did not explore the presence of floppy eyelid syndrome, as this syndrome is usually
associated with sleep apnea and constitutes as a common cause of ocular irritation [20,
21].
Future perspectives
Future studies should include a larger number of patients for a longer period of time.
Objective testing for dry eye disease should also be performed.
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Conclusions
When assuring good individual PAP mask interface adjustment, short-term PAP therapy
did not increase eye symptoms in sleep apnea patients. An initial PAP preparation is
therefore essential in preventing the emergence of eye symptoms.
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Age, years 46 56.0 15.9
BMI, kg/m2 46 31.7 6.0
CCI 46 1.8 2.3
AHI/h 46 34.1 21.8
ODI3/h 45 34.4 20.7
SPO2 mean 46 91.6 2.9
nadir SPO2 44 79.1 8.2
CT90% 36 20.9 26.8




L/min 46 4.9 7.4
Unintentional leak, 95 th %,
L/min 46 19.4 13.2
Average PAP usage/day,
h:min 46 4:09 2:16
Median PAP usage/day,
h:min 46 5:11 2:15
Abbreviations: BMI = body mass index; CCI = age-adjusted Charlson
comorbidity index; AHI = apnea and hypopnea index; ODI3 = Oxygen
desaturation index of 3%; CT90% = Cumulative time with SpO2 under 90%;
Average PAP use = total  hours used /  total  days; Median PAP use = total
hours used/PAP used days
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Figure 1: Dry eye symptom values with PAP therapy at four days and two months. No
significant difference was found.
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Figure  2:  Watering  values,  at  baseline  and  with  PAP  therapy  (at  four  days  and  two
months). No significant difference was found.
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Figure 3: Bivariate Pearson correlation between left and right eye watering values and
PAP 95th air-leak values at two months of PAP therapy.
